Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis

Lanzhu Yue, PhD, Matthias Bartenstein, Wanke Zhao, Wan-Ting Ho, Ling Zhang, MD, Franck Rapaport, PhD, Ross L. Levine, MD, Zonghong Shao, Zhizhuang Joe Zhao, PhD, Amit Verma, Pearlie K Epling-Burnette, PhD

Blood (2015) 126 (23): 603.

https://doi.org/10.1182/blood.V126.23.603.603

Published: 2015

Journal Articles

Mesenchymal Cell Associated Fibrosis in Experimental mpl W515L Mouse Model of Myelofibrosis

Lanzhu Yue, PhD, Ying Han, MD, Ling Zhang, MD, Sheng Wei, MD, Xiubao Ren, MD, Zonghong Shao, Pearlie K Epling-Burnette, PhD

Blood (2015) 126 (23): 604.

https://doi.org/10.1182/blood.V126.23.604.604

Published: 2015

Journal Articles

Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)

Rami S. Komrokji, MD, Mintallah Haider, MD, Najla H. Al Ali, BDS, MSc, Jeffrey E Lancet, MD, Qing Zhang, MD, Pearlie K Epling-Burnette, PhD, Alan F. List, MD, Eric Padron, MD

Blood (2015) 126 (23): 1664.

https://doi.org/10.1182/blood.V126.23.1664.1664

Published: 2015

Journal Articles

Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition

Matthew S Beatty, PhD, Rebecca S Hesterberg, BA, Ying Han, MD, Eric Padron, MD, Adam W Mailloux, PhD, Sean Yoder, M.S, Anjali M Rajadhyaksha, PhD, Alan F. List, MD, Pearlie K Epling-Burnette, PhD

Blood (2015) 126 (23): 286.

https://doi.org/10.1182/blood.V126.23.286.286

Published: 2015

Journal Articles

Prognostic Value of Circulating Myeloblasts in Patients with Myelodysplastic Syndromes (MDS): A Proposal for Incorporation in the Revised International Prognostic Scoring System (R-IPSS)

Rami S Komrokji, MD, Eric Padron, MD, Najla H Al Ali, Jeffrey E Lancet, MD, Jeff Hall, PhD, Brian Kwok, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, PhD, Alan F List, MD

Blood (2014) 124 (21): 4650.

https://doi.org/10.1182/blood.V124.21.4650.4650

Published: 2014

Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Rami S Komrokji, MD, Sheng Wei, MD, Adam W Mailloux, PhD, Ling Zhang, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Sara Tinsley, ARNP, Lisa A Nardelli, BS, CCRP, Cynthia Benoit, RN, Javier Pinilla-Ibarz, MD PhD, Pearlie K Epling-Burnette, PhD, Alan F List, MD

Blood (2014) 124 (21): 4653.

https://doi.org/10.1182/blood.V124.21.4653.4653

Published: 2014

Journal Articles

Common γ Chain (γ c ) Cytokine Hypersensitivity Leads To T-Cell Homeostatic Deregulation Independent Of STAT3 Mutation In Large Granular Lymphocyte Leukemia

Adam W Mailloux, PhD, Jeff Painter, BS, Eric Padron, MD, Thomas P. Loughran, Jr., M.D., Pearlie K Epling-Burnette, PhD

Blood (2013) 122 (21): 1628.

https://doi.org/10.1182/blood.V122.21.1628.1628

Published: 2013

Journal Articles

The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)

Amer M. Zeidan, MD, Najla H Al Ali, Mohamed A. Kharfan-Dabaja, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E Lancet, MD, Alan F List, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 2771.

https://doi.org/10.1182/blood.V122.21.2771.2771

Published: 2013

Journal Articles

JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause Of Mutation-Independent RNA Splicing Aberrancy In CMML

Sateesh Kunigal, PhD, Jamie Teer, PhD, Jeff Painter, BS, Sean J Yoder, MS, Euhnee Kim, PhD, Ling Zhang, MD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Omar Abdel-Wahab, MD, Alan List, MD, Pearlie K Epling-Burnette, PhD, Eric Padron, MD

Blood (2013) 122 (21): 2772.

https://doi.org/10.1182/blood.V122.21.2772.2772

Published: 2013

Journal Articles

Characterization Of RING Finger E3-Ubiquitin Ligase Cereblon In Hematopoietic Regulation

Ying Han, MD, Anjali M Rajadhyaksha, PhD, Adam W Mailloux, PhD, Jeff Painter, BS, Jessica M. McDaniel, PhD, Ling Zhang, MD, Pearlie K Epling-Burnette, PhD

Blood (2013) 122 (21): 1207.

https://doi.org/10.1182/blood.V122.21.1207.1207

Published: 2013

Journal Articles

Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases

Rami S Komrokji, MD, Austin G Kulasekararaj, MBBS, MD, MRCP, FRCP, Najla H Al Ali, Shahram Y Kordasti, MD, PhD, Emily Bart-smith, Craig Benjamin, Eric Padron, MD, Ling Zhang, MD, Jeffrey E Lancet, MD, Alan List, MD, Ghulam J Mufti, FRCP, FRCPath, M.D., Pearlie K Epling-Burnette, PhD

Blood (2013) 122 (21): 746.

https://doi.org/10.1182/blood.V122.21.746.746

Published: 2013

Journal Articles

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

Pearlie K Epling-Burnette, PhD, Ying Han, MD, Adam W Mailloux, PhD, Ling Zhang, MD, Jessica M. McDaniel, PhD, Rajadhyaksha Anjali, PhD, Sheng Wei, MD, Ritchie David, PhD, Paul Neeson, PhD, Rami S. Komrokji, MD, Alan List, MD

Blood (2013) 122 (21): 748.

https://doi.org/10.1182/blood.V122.21.748.748

Published: 2013

Journal Articles

SRSF2 Mutations Impair Nuclear Aggregation and Represent a Novel Mechanism Of Spliceosomal Dysregulation In CMML

Eric Padron, MD, Sateesh Kunigal, PhD, Xiaoyi Ren, Jeffrey S. Painter, B.S., Rainer Metcalf, Joseph Johnson, Ling Zhang, MD, Jeffrey E Lancet, MD, Rami S Komrokji, MD, Kenyon Daniels, PhD, Alan List, MD, Pearlie K Epling-Burnette, PhD

Blood (2013) 122 (21): 260.

https://doi.org/10.1182/blood.V122.21.260.260

Published: 2013

Journal Articles

Pluripotent Fibrosis Initiating Mesenchymal Stromal Cell Linked To Cytopenias In LGL Leukemia Through Genetic Reprogramming

Pearlie K. Epling-Burnette, PhD, Adam W. Mailloux, PhD, Ling Zhang, MD, Lynn C. Moscinski, MD, Sheng Wei, MD, Sean J Yoder, MS, Lubomir Sokol, MD, Ph.D, Loughran P Thomas, MD

Blood (2013) 122 (21): 1218.

https://doi.org/10.1182/blood.V122.21.1218.1218

Published: 2013

Journal Articles

A Comparison of Prognostic Models for Chronic Myelomonocytic Leukemia (CMML) in the Era of Hypomethylating Agents

Eric Padron, MD, Najla H Al Ali, Deniz Peker, MD, Jeffrey E Lancet, MD, Pearlie K Epling-Burnette, PhD, Ling Zhang, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 1695.

https://doi.org/10.1182/blood.V120.21.1695.1695

Published: 2012

Journal Articles

Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes

Jeffrey S Painter, BS, Jong Park, PhD, Michael J Clemente, Christine L. O'Keefe, PhD, Sheng Wei, MD, Jaroslaw P. Maciejewski, MD, PhD, Ron Paquette, MD, PhD, Thomas P. Loughran, Jr., M.D., Alan F. List, MD, Pearlie K Epling-Burnette, PhD

Blood (2011) 118 (21): 2412.

https://doi.org/10.1182/blood.V118.21.2412.2412

Published: 2011

Journal Articles

Tobacco Use Influences Disease Outcome and AML Potential in Myelodysplastic Syndromes,

Rami S. Komrokji, MD, Dana E Rollison, PhD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 3790.

https://doi.org/10.1182/blood.V118.21.3790.3790

Published: 2011

Journal Articles

Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Asmita Mishra, MD, Dana E Rollison, PhD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2011) 118 (21): 5018.

https://doi.org/10.1182/blood.V118.21.5018.5018

Published: 2011

NARROW

Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis

Mesenchymal Cell Associated Fibrosis in Experimental mpl W515L Mouse Model of Myelofibrosis

Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)

Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition

Prognostic Value of Circulating Myeloblasts in Patients with Myelodysplastic Syndromes (MDS): A Proposal for Incorporation in the Revised International Prognostic Scoring System (R-IPSS)

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Common γ Chain (γ c ) Cytokine Hypersensitivity Leads To T-Cell Homeostatic Deregulation Independent Of STAT3 Mutation In Large Granular Lymphocyte Leukemia

The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)

JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause Of Mutation-Independent RNA Splicing Aberrancy In CMML

Characterization Of RING Finger E3-Ubiquitin Ligase Cereblon In Hematopoietic Regulation

Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

SRSF2 Mutations Impair Nuclear Aggregation and Represent a Novel Mechanism Of Spliceosomal Dysregulation In CMML

Pluripotent Fibrosis Initiating Mesenchymal Stromal Cell Linked To Cytopenias In LGL Leukemia Through Genetic Reprogramming

A Comparison of Prognostic Models for Chronic Myelomonocytic Leukemia (CMML) in the Era of Hypomethylating Agents

Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes

Tobacco Use Influences Disease Outcome and AML Potential in Myelodysplastic Syndromes,

Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only